Jun 17, 2020 / 05:00PM GMT
Pat Furlong - Parent Project Muscular Dystrophy - Moderator
Welcome, everyone. Good morning, good afternoon, or good evening from wherever you have called in. We're really pleased that you're here. My name is Pat Furlong and I'm from PPMD, and we're welcoming today, the Antisense Therapeutics group. Mark Diamond is here as well as his colleague, Nuket Desem.
They have considerable experience in drug development. And I think for our community, this might be a little confusing with Antisense Therapeutics and our Antisense oligonucleotides that are exon-skipping drugs. These -- the drug ATL1102, that they're going to present to you has a different mode of action. So I hope you listen, this is a great opportunity, and this particular approach would apply to every young man with Duchenne muscular dystrophy.
So with that, I'll turn it over to Mark Diamond to begin. Mark?
Mark Diamond - Antisense Therapeutics Limited - CEO & MD
Thank you. Thank you, Pat, and the team at PPMD for the opportunity to speak today on Antisense Therapeutics Duchenne
Antisense Therapeutics Ltd Phase II Trial Final Data Results Webinar Transcript
Jun 17, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers